ESR1 and breast carcinoma: Recent studies have shown that IMP3 expression is closely associated with estrogen receptor negativity and positive expression of EGFR.[19] IMP3 acts as a promoter of aggressive behavior in triple negative breast cancer and contributes to breast cancer chemo resistance.